Ra-226 (T1/2: 1600 y) has a long history in the medical field, and is once again becoming attractive for production of new radionuclides in the niche of Targeted Alpha Therapy (TAT). Cyclotron irradiation can produce the short-lived Ac-225 (T1/2: 10 d) by the nuclear reaction Ra-226 (p,2n) Ac-225. After irradiation, Ac-225 is separated from Ra-226 and its progeny, and intensely purified for clinical applications. Next, the rare and valuable Ra-226 needs to be recycled as much as possible, while minimizing radioactive waste. A number of feasible separation and purification schemes were identified, that each require different approaches to recycle the Ra-226 target material. The liquid waste containing traces of Ra-226 also require special treatment options, that often rely on a sulfate (co-)precipitation step for final decontamination.